



Oryn Therapeutics, LLC

Company Logo Goes Here

Contact:
Richard Selsted

Location:
San Francisco,
Ca

Email:
rselsted@oryntherapeutics.com

Tel:
415.948.3414

Website:
oryntherapeutics.com



Company Profile

Industry Sector: Bio-technology

Company Overview: Oryn Therapeutics was founded with the goal of translating new discoveries about the body's innate immune system into therapies for immunologic, autoimmune, and infectious diseases. The Company has developed Orynotides, therapeutic molecules based on bioactive cyclic peptides discovered in non-human primates. The drug development strategy exploits a **retroevolutionary** approach whereby molecules lost during primate evolution, and thus absent in humans, are re-introduced as therapeutics.

Target Market(s): Pharma



Key Value Drivers

Technology*: Oryn's core technology platform focuses on the design and testing of theta-defensin-derived peptides with demonstrated efficacy in animal models of autoimmune, inflammatory, and infectious diseases

Competitive Advantage: Orynotides are safe, stable, and non-immunogenic. This lack of immune response makes them suitable for long term, repeat administration. Orynotides are highly stable *in vitro* and *in vivo* with a 2 year shelf life

Plan & Strategy: Accomplish CMC, Regulatory, Non-clinical, and Phase 1 clinical by mid 2017



Management

Leadership: Robert Erwin, CEO; Michael Selsted Ph.D, M.D., Chief Scientist; Jane Emerson M.D., Ph.D, Chief Medical Officer; Richard Selsted, COO

Scientific Advisory Board:

David M. Essayan, M.D., F.A.C.P.

Mike Gresser, Ph.D.

Percio S. Gulko, M.D.



Product Pipeline

1. Immunoregulatory Orynotides are effective in animal models of autoimmune arthritis and severe sepsis. Three Orynotide analogs have shown superior efficacy to leading FDA approved rheumatoid arthritis (RA) drugs. Unlike existing RA treatments, Orynotides show no immunocompromising side effects.

2. Antimicrobial Orynotides are effective in animal models of bacterial, polymicrobial, and viral infectious diseases including multi-drug resistant bacterial and fungal pathogens. Orynotides exert their antimicrobial effects through a unique mode of action that greatly limits the emergence of Orynotide resistance.



Small Business Innovation Research (SBIR)
Small Business Technology Transfer (STTR)

National Institutes of Health
Commercialization Assistance Program (NIH CAP)

